A Phase II Trial of 4 Weeks of Glecaprevir/Pibrentasvir
for Early Hepatitis C Virus: ACTG A5380
CROI 2024 March 3-6 Denver
Arthur Kim, Minhee Kang, Triin Umbleja, Estevao P. Nunes, Kristen Marks, Chanelle Wimbish, Daniel S. Fierer, Annie Luetkemeyer, Dimas Kleimann, Sunil Suhas Solomon, Leonard Sowah, Beverly L. Alston-Smith, David L. Wyles, Susanna Naggie, for the A5380 Study Team
